Effect of alpha interferon (IFN-α) on 2′-5′ oligoadenylate synthetase activity in peripheral blood mononuclear cells of patients with chronic hepatitis C: Relationship to the antiviral effect of IFN-α

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 2, 1996, Pages 320-324

  Pawlotsky, Jean Michel ^a   Hovanessian, Ara G ^b   Roudot Thoraval, Françoise ^a   Robert, Nadine ^b   Bouvier, Magali ^a   Babany, Gérard ^c   Duval, Jean ^a   Dhumeaux, Daniel ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b INSTITUT PASTEUR   (France)

^c Roche Laboratories   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ALANINE AMINOTRANSFERASE; ISOENZYME; RECOMBINANT ALPHA2A INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; ENZYME INDUCTION; FEMALE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

2',5'-OLIGOADENYLATE SYNTHETASE; ADULT; ANTIVIRAL AGENTS; ENZYME INDUCTION; FEMALE; HEPATITIS C; HUMANS; INTERFERON ALFA-2A; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TIME FACTORS;

EID: 0030052432     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.2.320     Document Type: Article

References (36)

1. Alter, H. J. 1995. To C or not to C. these are the questions. Blood 85: 1681-1695
2. Baron, S., S. K. Tyring, W. R. Fleischmann, D. H. Coppenhaver, D. W. Niesel, G. R. Klimpel, G. J. Stanton, and T. K. Hughes. 1991 The interferons. Mechanisms of action and clinical applications. JAMA 266:1375-1383.
3. Barouki, F. M., F. R. Witter, D. E. Griffin, P. I. Nadler, A. Woods, D. L. Wood, and P. S. Lietman. 1987. Time course of interferon levels, antiviral state, 2′,5′-oligoadenylate synthetase and side effects in healthy men J. Interferon Res. 7:29-39
4. Buffet-Janvresse, C., H. Magard, N. Robert, and A. G. Hovanessian. 1983. Assay and the levels of 2-5A-synthetase in lymphocytes of patients with viral, bacterial and autoimmune diseases. Ann. Inst. Pasteur Immunol. 134:247-258.
5. Giannelli, G., G. Antonelli, G. Fera, F. Dianzani, and O. Schiraldi. 1993. 2′,5′-oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C. J. Interferon Res. 13:57-60.
6. Hoofnagle, J. H., K. D. Mullen, D. B. Jones, V. Rustgi, A. Di Bisceglie, M. Peters, J. G. Waggoner, Y. Park, and E. A. Jones. 1986. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 315:1575-1578.
7. Hovanessian, A. G. 1993. Interferon-induced dsRNA-activated protein kinase (PKR): antiproliferative, antiviral and antitumoral functions. Semin. Virol. 4:237-245.
8. Hovanessian, A. G., A. G. Laurent, J. Chebath, J. Galabru, N. Robert, and J. Svab. 1987 Identification of 69-kd and 100-kd forms of 2-5A synthetase in interferon-treated human cells by specific monoclonal antibodies. EMBO J. 6:1273-1280.
9. Hovanessian, A. G., J. Svab, I. Marié, N. Robert, S. Chamaret, and A. G. Laurent. 1988. Characterization of 69- and 100-kDa forms of 2-5A-synthetase from interferon-treated human cells. J Biol. Chem. 263:4945-4949.
10. Ikeda, T., A. M. L. Lever, and H. C. Thomas. 1986. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology 6:962-965.
11. Kakumu, S., M. Arao, K. Yoshioka, H. Ichimiya, K. Murase, T. Aoi, and A. Kusakabe. 1989. Pilot study of recombinant human α-interferon for chronic non-A, non-B hepatitis. Am J. Gastroenterol. 84:40-45
12. Lefkowitch, J. H., E. R. Schiff, G. L. Davis, R. P. Perillo, K. Lindsay, H. C. Bodenheimer, L. A. Balart, T. J. Ortego, J. Payne, J. L. Dienstag, A. Gibas, I. M. Jacobson, C. H. Tamburro, W. Carey, C. O'Brien, R. Sampliner, D. H. Van Thiel, D. Feit, J. Albrecht, C. Meschievitz, B. Sanghvi, R. D. Vaughan, and the Hepatitis Interventional Therapy Group. 1993. Pathological diagnosis of chronic hepatitis C. a multicenter comparative study with chronic hepatitis B. Gastroenterology 104:595-603.
13. Marié, I., J. Galabru, J. Svab, and A. G. Hovanessian. 1989. Preparation and characterization of polyclonal antibodies specific for the 69 and 100 K-dalton forms of human 2-5A synthetase. Biochem Biophys. Res. Commun. 160: 580-587.
14. Martinot-Peignoux, M., P. Marcellin, M. Pouteau, C. Castelnau, N. Boyer, M. Poliquin, C. Degott, I. Descombes, V. Le Breton, J. P. Benhamou, and S. Erlinger. 1995. Pretreatment serum HCV RNA levels and HCV genotype are the main and independent prognostic factors of sustained response to alpha interferon therapy in chronic hepatitis C. Hepatology 22:1050-1056.
15. Nishiguchi, S., T. Kuroki, S. Otani, T. Takeda, S. Hirota, Y. Shimizu, S. Nakajima, S. Saito, S. Shiomi, and K. Kobayashi. 1989. Relationship of the effects of interferon on chronic hepatitis B and the induction of 2′,5′-oligoadenylate synthetase. Hepatology 10:29-33.
16. Nishiguchi, S., T. Kuroki, T. Ueda, S. Hirota, A. Tamori, D. Habu, T. Takeda, Y. Shimizu, K. Kim, S. Nakajima, S. Shiomi, S. Seki, and K. Kobayashi. 1989 Clinical significance of 2′,5′-oligoadenylate synthetase activity in liver tissue. Gastroenterology 96:A639
17. Nousbaum, J. B., S. Pol, B. Nalpas, P. Landais, P. Berthelot, C. Bréchot, and the Collaborative Study Group. 1995 Hepatitis C virus type Ib (II) infection in France and Italy. Ann. Intern. Med. 122:161-168
18. Okada, S. I., Y. Akahane, H. Suzuki, H. Okamoto, and S. Mishiro. 1992 The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619-624
19. Pawlotsky, J. M., F. Darthuy, J. Rémiré, C. Pellet, L. Udin, L. Stuyver, F. Roudot-Thoraval, C. Duvoux, C. Douvin, A. Mallat, J. P. Mavier, J. M. Métreau, J. Duval, and D. Dhumeaux. 1995 Significance of anti-hepatitis C virus core IgM antibodies in patients with chronic hepatitis C. J. Med. Virol 47:285-291.
20. Pawlotsky, J. M., A. Fleury, V. Choukroun, L. Deforges, F. Roudot-Thoraval, P. Aumont, J. Duval, and D. Dhumecaux. 1994. Significance of highly positive c22-3 "indeterminate" second-generation hepatitis C virus (HCV) recombinant immunoblot assay (RIBA) and resolution by third-generation HCV RIBA. J. Clin. Microbiol 32:1357-1359.
21. Pawlotsky, J. M., A. G. Hovanessian, F. Roudot-Thoraval, P. Lebon, N. Robert, M. Bouvier, G. Babany, J. Duval, and D. Dhumeaux. 1995 Activity of the interferon-induccd 2′,5′-oligoadenylate synthetase in patients with chronic hepatitis C. J. Interferon Cytokine Res. 15:857-862.
22. Pawlotsky, J. M., F. Roudot-Thoraval, A. Bastie, F. Darthuy, J. Rémiré, J. M. Métreau, E. S. Zafrani, J. Duval, and D. Dhumeaux. J. Infect Dis., in press.
23. Pestka, S., J. A. Langer, K. C. Zoon, and C. E. Samuel. 1987. Interferons and their actions Annu. Rev. Biochem. 56:727-777.
24. Poitrine, A., S. Chousterman, M. Chousterman, S. Naveau, M. N. Thang, and J. C. Chaput. 1985. Lack of in vivo activation of the interferon system in HBsAg-positive chronic active hepatitis. Hepatology 5:171-174.
25. Read, S. E., B. R. G. Williams, R. A. Coates, W. K. Evans, M. M. Fanning, M. B. Garvey, and F. A. Shepherd. 1985. Elevated levels of interferon-induced 2′-5′ oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome J Infect Dis. 152: 466-472.
26. Saracco, G., F. Rosina, M. L. Abate, L. Chiandussi, V. Gallo, E. Cerutti, A. Di Napoli, A. Solinas, A. Deplano, A. Tocco, P. Cossu, D. Chien, G. Kuo, A. Polito, A. J. Weiner, M. Houghton, G. Verme, F. Bonino, and M. Rizzetto. 1993. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon α-2b. Hepatology 18:1300-1305.
27. Sawai, H., H. Taira, K. Ishibashi, M. Itoh, H. Tanaka, and K. Shigenobu. 1988. Detection of 2′-5′ oligoadenylate synthetase activity in serum and in supernatant of cultivated lymphocytes: response to interferons or interferon inducers. Biomed. Res 9:59-66
28. Schattner, A., D. Wallach, G. Merlin, T. Hahn, S. Levin, B. Ramot, and M. Revel. 1982. Variation of (2′-5′) oligo A synthetase level in lymphocytes and granulocytes of patients with viral infections and leukemia. J. Interferon Res. 2:355-361.
29. Scheuer, P. J., P. Ashrafzadeh, S. Sherlock, D. Brown, and G. M. Dusheiko. 1992. The pathology of hepatitis C. Hepatology 15:567-571
30. Shindo, M., T. Okuno, M. Matsumoto, M. Takeda, T. Takino, J. Sokawa, A. Iwata, and Y. Sokawa. 1988. Serum 2′,5′-oligoadenylate synthetase activity during interferon treatment of chronic hepatitis B. Hepatology 8:366-370
31. Staeheli, P., O. Haller, W. Boll, J. Lindemann, and C. Weissman. 1986. Mx protein, constitutive expression in 3T3 cells transformed with cloned Mx cDNA confers selective resistance to influenza virus. Cell 44:147-158.
32. Tine, F., S. Magrin, A. Craxi, and L. Pagliaro. 1991. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. J. Hepatol 13:192-199.
33. Virelizier, J. L. 1989. The immune system: an update for virologists, p. 1-13. In N. J. Dimmoch and P. D. Minor (ed.), Immune responses, virus infections and disease - 1989. IRL Press, Oxford.
34. Witt, P. L., I. Marié, N. Robert, A. Irizarry, E. C. Borden, and A. G. Hovanessian. 1993. Isoforms p69 and p100 of 2′,5′-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro. J. Interferon Res. 13:17-23.
35. Witter, F., F. Barouki, D. Griffin, P. Nadler, A. Woods, D. Wood, and P. Lietman. 1987. Biologic response (antiviral) to recombinant human interferon alpha-2a as a function of dose and route of administration in healthy volunteers. Clin Pharmacol Ther. 42:567-575.
36. Zachoval, R., M. Kroener, M. Brommer, and F. Deinhardt. 1990. Serology and interferon production during the early phase of acute hepatitis A. J. Infect. Dis. 161:353-354.